Business
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Updat...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n.prnbcc{\nBORDER-TOP:0pt solid; BORDER-RIGHT:0pt solid; BORDER-COLLAPSE: COLLAPSE; BORDER-BOTTOM:0pt solid; BORDER-LEFT:0pt solid\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, BC, Sept. 2, 2020\n\n\n\nTSX:INOTCQX:IMLFF \n VANCOUVER, BC, Sept. 2, 2020 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX: IN) (OTCQX: IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the fiscal year ended June 30, 2020, on Tuesday, September 8, 2020.\nConference Call & Webcast:Tuesday, September 8, 2020 at 8:30 AM Pacific Time, 11:30 AM Eastern Time\nLocal - Toronto\n(+1) 416-764-8609\nLocal - Vancouver\n(+1) 778-383-7417\nToll Free - North America\n(+1) 888-390-0605\nConference ID:\n56741577\nWebcast: https://produceredition.webcasts.com/starthere.jsp?ei=1361200&tp_key=f6c5efad81 \nReplays, Available through September 22, 2020: \nToronto:\n(+1) 416-764-8677\nNorth America (Toll Free):\n(+1) 888-390-0541\nPlayback Passcode:\n741577 #\nThe Company's full financial statements and related MD&A for the fiscal year ended June 30, 2020 will be available at www.inmedpharma.com and at www.sedar.com prior to the September 8, 2020 conference call.\nAbout InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN), in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based me...